{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T06:09:06Z","timestamp":1787724546024,"version":"build-2784847793"},"reference-count":92,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2024,2,19]],"date-time":"2024-02-19T00:00:00Z","timestamp":1708300800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Hodgkin lymphoma is characterized by a high cure rate in the modern era of medicine regardless of stage, but patients suffer from a high risk of comorbidity associated with the administered therapy. The main aim of this review article is to assess and analyze the various comorbidities associated with Hodgkin lymphoma and address the survivorship of patients, including fertility, secondary cancers due to cardiovascular toxicity, and quality of life. Furthermore, this review explores the optimal strategy for detecting relapse. The treatment paradigm of Hodgkin lymphoma has shifted, with a paradigm shift toward achieving a high cure rate and low toxicity as a standard of care in this patient population. Checkpoint inhibitors, especially nivolumab, in combination with chemotherapy are increasingly being studied in the first line of therapy. However, their long-term toxicity remains to be assessed in longer follow-up. In conclusion, Hodgkin lymphoma survivors, regardless of their treatment, should be followed up individually by a multidisciplinary survivorship team in order to detect and properly treat the long-term side effects of therapy.<\/jats:p>","DOI":"10.3390\/medicina60020344","type":"journal-article","created":{"date-parts":[[2024,2,19]],"date-time":"2024-02-19T11:23:57Z","timestamp":1708341837000},"page":"344","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["How I Follow Hodgkin Lymphoma in First Complete (Metabolic) Remission?"],"prefix":"10.3390","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0069-6688","authenticated-orcid":false,"given":"Vibor","family":"Milunovi\u0107","sequence":"first","affiliation":[{"name":"Division of Hematology, Clinical Hospital Merkur, 10000 Zagreb, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,2,19]]},"reference":[{"key":"ref_1","unstructured":"(2023, September 16). SEER Cancer Stat Facts: Hodgkin Lymphoma, Available online: https:\/\/seer.cancer.gov\/statfacts\/html\/hodg.html."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"41","DOI":"10.5694\/j.1326-5377.1972.tb106491.x","article-title":"Combination chemotherapy (MOPP) in the man-agement of advanced Hodgkin\u2019s disease. A progress report on 55 patients","volume":"1","author":"Cooper","year":"1972","journal-title":"Med. J. Aust."},{"key":"ref_3","unstructured":"ASCO Connection (2023, September 16). ASCO Announces \u201cTop 5\u201d Advances in Modern Oncology. Available online: https:\/\/connection.asco.org\/magazine\/features\/asco-announces-%E2%80%9Ctop-5%E2%80%9D-advances-modern-oncology."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1200\/JCO.19.00964","article-title":"Positron Emission Tomography\u2013Guided Treatment in Early-Stage Favorable Hodgkin Lymphoma: Final Results of the International, Randomized Phase III HD16 Trial by the German Hodgkin Study Group","volume":"37","author":"Fuchs","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_5","first-page":"CD007941","article-title":"Comparison of first-line chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for people with early unfavourable or advanced stage Hodgkin lymphoma","volume":"5","author":"Skoetz","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1016\/S0140-6736(17)32134-7","article-title":"PET-guided treatment in patients with advanced-stage Hodgkin\u2019s lymphoma (HD18): Final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group","volume":"390","author":"Borchmann","year":"2017","journal-title":"Lancet"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa1100340","article-title":"ABVD versus BEACOPP for Hodgkin\u2019s Lymphoma When High-Dose Salvage Is Planned","volume":"365","author":"Viviani","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1056\/NEJMoa2206125","article-title":"Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin\u2019s Lymphoma","volume":"387","author":"Ansell","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa1510093","article-title":"Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin\u2019s Lymphoma","volume":"374","author":"Johnson","year":"2016","journal-title":"New Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Vellemans, H., and Andr\u00e9, M.P.E. (2021). Review of Treatment Options for the Management of Advanced Stage Hodgkin Lymphoma. Cancers, 13.","DOI":"10.3390\/cancers13153745"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/S1470-2045(18)30784-8","article-title":"PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): A randomised, multicentre, non-inferiority, phase 3 study","volume":"20","author":"Casasnovas","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1200\/JCO.2015.63.0699","article-title":"Interim Positron Emission Tomography Response\u2013Adapted Therapy in Advanced-Stage Hodgkin Lymphoma: Final Results of the Phase II Part of the HD0801 Study","volume":"34","author":"Zinzani","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1200\/JCO.2017.75.2543","article-title":"Early Chemotherapy Intensification with Escalated BEACOPP in Patients with Advanced-Stage Hodgkin Lymphoma with a Positive Interim Positron Emission Tomography\/Computed Tomography Scan After Two ABVD Cycles: Long-Term Results of the GITIL\/FIL HD 0607 Trial","volume":"36","author":"Gallamini","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1200\/JCO.2015.63.1119","article-title":"US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose\u2013Positron Emission Tomography Imaging: Southwest Oncology Group S0816","volume":"34","author":"Press","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Viviani, S., Vanazzi, A., Frassoni, S., Rusconi, C., Rossi, A., Romano, A., Patti, C., Schiavotto, C., Sorasio, R., and Marasco, V. (Leuk. Lymphoma, 2024). High-dose chemotherapy and autologous stem cell transplant as first salvage treatment for relapsed or refractory Hodgkin Lymphoma in the era of PET-adapted strategies, Leuk. Lymphoma, online ahead of print.","DOI":"10.1080\/10428194.2023.2298273"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1365-2141.2008.06998.x","article-title":"Managing relapsed and refractory Hodgkin lymphoma","volume":"141","author":"Brice","year":"2008","journal-title":"Br. J. Haematol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1080\/17474086.2020.1793666","article-title":"Efficacy and safety of front-line treatments for advanced Hodgkin lymphoma: A systematic literature review","volume":"13","author":"Dalal","year":"2020","journal-title":"Expert Rev. Hematol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"iv19","DOI":"10.1093\/annonc\/mdy080","article-title":"Hodgkin lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Eichenauer","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/bjh.18083","article-title":"Guideline for the first-line management of Classical Hodgkin Lymphoma\u2014A British Society for Haematology guideline","volume":"197","author":"Follows","year":"2022","journal-title":"Br. J. Haematol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"322","DOI":"10.6004\/jnccn.2022.0021","article-title":"NCCN Guidelines\u00ae Insights: Hodgkin Lymphoma, Version 2.2022","volume":"20","author":"Hoppe","year":"2022","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.currproblcancer.2010.04.007","article-title":"ACR Appropriateness Criteria: Follow-Up of Hodgkin\u2019s Lymphoma","volume":"34","author":"Ng","year":"2010","journal-title":"Curr. Probl. Cancer"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1200\/JCO.2008.16.1513","article-title":"Role of [18F]Fluorodeoxyglucose Positron Emission Tomography Scan in the Follow-Up of Lymphoma","volume":"27","author":"Zinzani","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1002\/cncr.29277","article-title":"Very low utility of surveillance imaging in early-stage classic Hodgkin lymphoma treated with a combination of doxorubicin, bleomycin, vinblastine, and dacarbazine and radiation therapy","volume":"121","author":"Gandikota","year":"2015","journal-title":"Cancer"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.clml.2020.02.008","article-title":"Imaging Surveillance of Limited-stage Classic Hodgkin Lymphoma Patients After PET\u2013CT-documented First Remission","volume":"20","author":"Glober","year":"2020","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3835","DOI":"10.1002\/cncr.25240","article-title":"Surveillance imaging of Hodgkin lymphoma patients in first remission: A clinical and economic analysis","volume":"116","author":"Lee","year":"2010","journal-title":"Cancer"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, stag-ing, and response assessment of Hodgkin and non-Hodgkin lymphoma: The Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1093\/annonc\/mdp522","article-title":"Positron emission tomography at the end of first-line therapy and during follow-up in patients with Hodgkin lymphoma: A retrospective study","volume":"21","author":"Mocikova","year":"2010","journal-title":"Ann. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"931","DOI":"10.3324\/haematol.2011.056010","article-title":"Positron emission tomography\/computed tomography surveillance in patients with Hodgkin lymphoma in first remission has a low positive predictive value and high costs","volume":"97","author":"Mylam","year":"2012","journal-title":"Haematologica"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Oreiro, M.B., Mart\u00edn, R., Gomez, P., Mu\u00f1oz, N.L., Rodriguez, A., Li\u00e9bana, M., Navarro, B., S\u00e1nchez-Gonz\u00e1lez, B., Mar\u00ed, P., and de Oteiza, J.P. (2021). SEGHI Study: Defining the Best Surveillance Strategy in Hodgkin Lymphoma after First-Line Treatment. Cancers, 13.","DOI":"10.3390\/cancers13102412"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1001\/archinternmed.2009.427","article-title":"Radiation Dose Associated with Common Computed Tomography Examinations and the Associated Lifetime Attributable Risk of Cancer","volume":"169","author":"Lipson","year":"2009","journal-title":"Arch. Intern. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1148\/radiol.14132154","article-title":"Advanced-stage Hodgkin Lymphoma: US\/Chest Radiography for Detection of Relapse in Patients in First Complete Remission\u2014A Randomized Trial of Routine Surveillance Imaging Procedures","volume":"272","author":"Picardi","year":"2014","journal-title":"Radiology"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/bjh.18180","article-title":"Late recurrence of lymphoid malignancies after initial treatment for Hodgkin lymphoma\u2014A study from the Danish Lymphoma Registry","volume":"198","author":"Andersen","year":"2022","journal-title":"Br. J. Haematol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1200\/JCO.2016.71.3289","article-title":"Late Relapse of Classical Hodgkin Lymphoma: An Analysis of the German Hodgkin Study Group HD7 to HD12 Trials","volume":"35","author":"Goergen","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1002\/hon.3131","article-title":"Long-term outcomes in Hodgkin lymphoma survivors. Temporary trends and comparison with general population","volume":"41","author":"Clemente","year":"2023","journal-title":"Hematol. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1186\/1471-2407-12-197","article-title":"Risk of second breast cancer in female Hodgkin\u2019s lymphoma survivors: A meta-analysis","volume":"12","author":"Ibrahim","year":"2012","journal-title":"BMC Cancer"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ijrobp.2016.10.004","article-title":"Secondary Breast Cancer Risk by Radiation Volume in Women with Hodgkin Lymphoma","volume":"97","author":"Conway","year":"2017","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"5088","DOI":"10.1200\/JCO.2010.29.5683","article-title":"Long-Term Survival Among Patients with Hodgkin\u2019s Lymphoma Who Developed Breast Cancer: A Population-Based Study","volume":"28","author":"Milano","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"103175","DOI":"10.1016\/j.critrevonc.2020.103175","article-title":"Current overview and special considerations for second breast cancer in Hodgkin lymphoma survivors","volume":"157","author":"Bakkach","year":"2021","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1200\/JCO.2002.08.031","article-title":"Breast Cancer Screening in Women Previously Treated for Hodgkin\u2019s Disease: A Prospective Cohort Study","volume":"20","author":"Diller","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/S1470-2045(05)70387-9","article-title":"Lung cancer after treatment for Hodgkin\u2019s lymphoma: A systematic review","volume":"6","author":"Lorigan","year":"2005","journal-title":"Lancet Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Lin, L., Wang, D., and Chen, H. (2023). The characteristics and survival of second primary lung cancer after Hodgkin\u2019s lymphoma: A comparison with first primary lung cancer using the SEER database. PLoS ONE, 18.","DOI":"10.1371\/journal.pone.0285766"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1007\/s11606-020-05951-7","article-title":"Lung Cancer Screening with Low-Dose CT: A Meta-Analysis","volume":"35","author":"Hoffman","year":"2020","journal-title":"J. Gen. Intern. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.beha.2019.02.007","article-title":"Clinicopathological aspects of therapy-related acute myeloid leukemia and myelodysplastic syndrome","volume":"32","author":"Chua","year":"2019","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1046\/j.1365-2141.2002.03564.x","article-title":"Fifteen-year secondary leukaemia risk observed in 761 patients with Hodgkin\u2019s disease prospectively treated by MOPP or ABVD chemotherapy plus high-dose irradiation","volume":"118","author":"Delwail","year":"2002","journal-title":"Br. J. Haematol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1200\/JCO.2012.44.5791","article-title":"Risk of Therapy-Related Secondary Leukemia in Hodgkin Lymphoma: The Stanford University Experience Over Three Generations of Clinical Trials","volume":"31","author":"Koontz","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1182\/blood-2013-07-512657","article-title":"Therapy-related acute myeloid leukemia and myelodysplastic syndromes in patients with Hodgkin lymphoma: A report from the German Hodgkin Study Group","volume":"123","author":"Eichenauer","year":"2014","journal-title":"Blood"},{"key":"ref_47","first-page":"CD008814","article-title":"Optimisation of chemotherapy and radiotherapy for untreated Hodgkin lymphoma patients with respect to second malignant neoplasms, overall and progression-free survival: Individual participant data analysis","volume":"2017","author":"Franklin","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1001\/jamainternmed.2015.1180","article-title":"Cardiovascular Disease After Hodgkin Lymphoma Treatment: 40-year disease risk","volume":"175","author":"Schaapveld","year":"2015","journal-title":"JAMA Intern. Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"e492","DOI":"10.1016\/S2352-3026(15)00153-2","article-title":"Cardiovascular disease after treatment for Hodgkin\u2019s lymphoma: An analysis of nine collaborative EORTC-LYSA trials","volume":"2","author":"Maraldo","year":"2015","journal-title":"Lancet Haematol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"8059","DOI":"10.1200\/jco.2010.28.15_suppl.8059","article-title":"Clinically significant delayed cardiac morbidity following ABVD chemotherapy for Hodgkin lymphoma: A population-based study","volume":"28","author":"Hodgson","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1179\/joc.2006.18.2.199","article-title":"Evaluation of Acute and Early Cardiotoxicity in Survivors of Hodgkin\u2019s Disease Treated with ABVD or BEACOPP Regimens","volume":"18","author":"Elbl","year":"2006","journal-title":"J. Chemother."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s12012-020-09589-z","article-title":"Chemotherapy with a Pegylated Liposomal Doxorubicin-Containing Regimen in Newly Diagnosed Hodgkin Lymphoma Patients","volume":"21","author":"Liu","year":"2021","journal-title":"Cardiovasc. Toxicol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.ctrv.2010.12.004","article-title":"Screening Hodgkin lymphoma survivors for radiotherapy induced cardiovascular disease","volume":"37","author":"Bos","year":"2011","journal-title":"Cancer Treat. Rev."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.3324\/haematol.2011.045856","article-title":"Management of fertility in patients treated for Hodgkin\u2019s lymphoma","volume":"96","author":"Harel","year":"2011","journal-title":"Haematologica"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1023\/A:1012464703805","article-title":"Male gonadal dysfunction in patients with Hodgkin\u2019s disease prior to treatment","volume":"12","author":"Rueffer","year":"2001","journal-title":"Ann. Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.3324\/haematol.2009.009696","article-title":"Sperm quality before treatment in patients with early stage Hodgkin\u2019s lymphoma enrolled in EORTC-GELA Lymphoma Group trials","volume":"94","author":"Heutte","year":"2009","journal-title":"Haematologica"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1007\/s12094-020-02483-8","article-title":"ABVD and BEACOPP regimens\u2019 effects on fertility in young males with Hodgkin lymphoma","volume":"23","author":"Amin","year":"2021","journal-title":"Clin. Transl. Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Lambertini, M., Del Mastro, L., Pescio, M.C., Andersen, C.Y., Azim, H.A., Peccatori, F.A., Costa, M., Revelli, A., Salvagno, F., and Gennari, A. (2016). Cancer and fertility preservation: International recommendations from an expert meeting. BMC Med., 14.","DOI":"10.1186\/s12916-015-0545-7"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1093\/humrep\/det430","article-title":"Cryopreservation, semen use and the likelihood of fatherhood in male Hodgkin lymphoma survivors: An EORTC-GELA Lymphoma Group cohort study","volume":"29","author":"Heutte","year":"2014","journal-title":"Hum. Reprod."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"3978","DOI":"10.1182\/bloodadvances.2021005557","article-title":"Hodgkin lymphoma and female fertility: A multicenter study in women treated with doxorubicin, bleomycin, vinblastine, and dacarbazine","volume":"7","author":"Machet","year":"2023","journal-title":"Blood Adv."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1200\/JCO.2012.44.3721","article-title":"Gonadal Function and Fertility in Survivors After Hodgkin Lymphoma Treatment Within the German Hodgkin Study Group HD13 to HD15 Trials","volume":"31","author":"Behringer","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"3251","DOI":"10.1200\/JCO.21.00068","article-title":"Gonadal Function Recovery in Patients with Advanced Hodgkin Lymphoma Treated With a PET-Adapted Regimen: Prospective Analysis of a Randomized Phase III Trial (AHL2011)","volume":"39","author":"Demeestere","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1177\/03008916211040556","article-title":"Fertility preservation strategies for patients with lymphoma: A real-world practice survey among Fondazione Italiana Linfomi centers","volume":"108","author":"Viviani","year":"2022","journal-title":"Tumori J."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1093\/annonc\/mdq066","article-title":"No protection of the ovarian follicle pool with the use of GnRH-analogues or oral contraceptives in young women treated with escalated BEACOPP for advanced-stage Hodgkin lymphoma. Final results of a phase II trial from the German Hodgkin Study Group","volume":"21","author":"Behringer","year":"2010","journal-title":"Ann. Oncol."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Velasco, R., Domingo-Domenech, E., and Sureda, A. (2021). Brentuximab-Induced Peripheral Neurotoxicity: A Multidisciplinary Approach to Manage an Emerging Challenge in Hodgkin Lymphoma Therapy. Cancers, 13.","DOI":"10.3390\/cancers13236125"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"7485","DOI":"10.1182\/bloodadvances.2023010700","article-title":"Impact of cumulative dose of brentuximab vedotin on outcomes of frontline therapy for advanced-stage Hodgkin lymphoma","volume":"7","author":"Steiner","year":"2023","journal-title":"Blood Adv."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/bjh.15566","article-title":"Patient and physician preferences for first-line treatment of classical Hodgkin lymphoma in Germany, France and the United Kingdom","volume":"184","author":"McMullen","year":"2019","journal-title":"Br. J. Haematol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1016\/S0959-8049(03)00545-8","article-title":"Fatigue in long-term survivors of Hodgkin\u2019s lymphoma; a report from the German Hodgkin Lymphoma Study Group (GHSG)","volume":"39","author":"Flechtner","year":"2003","journal-title":"Eur. J. Cancer"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"3449","DOI":"10.1080\/10428194.2019.1641803","article-title":"Recognizing severe fatigue and decline in quality of life in Hodgkin lymphoma survivors","volume":"60","author":"Trachtenberg","year":"2019","journal-title":"Leuk. Lymphoma"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1080\/0284186X.2023.2168215","article-title":"Chronic fatigue in long-term survivors of Hodgkin\u2019s lymphoma after contemporary risk-adapted treatment","volume":"62","author":"Eikeland","year":"2023","journal-title":"Acta Oncol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1007\/s00277-013-1793-2","article-title":"Persisting fatigue in Hodgkin lymphoma survivors: A systematic review","volume":"92","author":"Oerlemans","year":"2013","journal-title":"Ann. Hematol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0885-3924(99)00148-7","article-title":"Fatigue and Psychiatric Morbidity Among Hodgkin\u2019s Disease Survivors","volume":"19","author":"Loge","year":"2000","journal-title":"J. Pain Symptom Manag."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"872329","DOI":"10.3389\/fpsyg.2022.872329","article-title":"Cancer-Related Psychological Distress in Lymphoma Survivor: An Italian Cross-Sectional Study","volume":"13","author":"Agostinelli","year":"2022","journal-title":"Front. Psychol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/0163-8343(93)90099-A","article-title":"Screening for depression and anxiety in cancer patients using the Hospital Anxiety and Depression Scale","volume":"15","author":"Carroll","year":"1993","journal-title":"Gen. Hosp. Psychiatry"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1080\/10428194.2021.1999445","article-title":"Risk of thyroid disorders in adult and childhood Hodgkin lymphoma survivors 40 years after treatment","volume":"63","author":"Jones","year":"2022","journal-title":"Leuk. Lymphoma"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1016\/S1470-2045(17)30696-4","article-title":"Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin\u2019s lymphoma: Final analysis of a phase 2 randomised trial by the German Hodgkin Study Group","volume":"18","author":"Eichenauer","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1002\/hon.3196_LBA5","article-title":"Brecadd is non-inferior to Ebeacopp in patients with advanced stage classical Hodgkin lymphoma: Efficacy results of the GHSG phase III HD21 Trial","volume":"41","author":"Borchmann","year":"2023","journal-title":"Hematol. Oncol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"3057","DOI":"10.1182\/blood-2023-188720","article-title":"Comprehensive Analysis of Treatment Related Morbidity and Progression\u2014Free Survival in the GHSG Phase III HD21 Trial","volume":"142","author":"Borchmann","year":"2023","journal-title":"Blood"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"4437","DOI":"10.1182\/blood-2023-188449","article-title":"Pregnancies and Childbirth Following Advanced-Stage Hodgkin Lym-phoma Treatment with Brecadd or Beacopp in the Randomized Phase III GHSG HD21 Trial","volume":"142","author":"Ferdinandus","year":"2023","journal-title":"Blood"},{"key":"ref_80","first-page":"9513701","article-title":"Immune Checkpoint Inhibition in Classical Hodgkin Lymphoma: From Early Achievements towards New Perspectives","volume":"2019","author":"Stalder","year":"2019","journal-title":"J. Oncol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1200\/JCO.19.00315","article-title":"Nivolumab for Newly Diagnosed Advanced-Stage Classic Hodgkin Lymphoma: Safety and Efficacy in the Phase II CheckMate 205 Study","volume":"37","author":"Ramchandren","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1002\/hon.3163_5","article-title":"Nivolumab(N)-AVD improves progression-free survival compared to Brentuximab vedotin(BV)-avd in advanced stage (AS) classic Hodgkin Lymphoma (HL): Results of Swog S1826","volume":"41","author":"Herrera","year":"2023","journal-title":"Hematol. Oncol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1056\/NEJMoa2206660","article-title":"Brentuximab Vedotin with Chemotherapy in Pediatric High-Risk Hodgkin\u2019s Lymphoma","volume":"387","author":"Castellino","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Witkowska, M., Majchrzak, A., and Smolewski, P. (2015). The Role of Radiotherapy in Hodgkin\u2019s Lymphoma: What Has Been Achieved during the Last 50 Years?. BioMed. Res. Int., 2015.","DOI":"10.1155\/2015\/485071"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/s41375-023-02064-y","article-title":"Follow-up of the GHSG HD16 trial of PET-guided treatment in early-stage favorable Hodgkin lymphoma","volume":"38","author":"Fuchs","year":"2023","journal-title":"Leukemia"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.ijrobp.2010.10.069","article-title":"Declining Use of Radiotherapy in Stage I and II Hodgkin\u2019s Disease and Its Effect on Survival and Secondary Malignancies","volume":"82","author":"Koshy","year":"2012","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1470-2045(20)30601-X","article-title":"PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): A multicentre, open-label, randomised, phase 3 trial","volume":"22","author":"Borchmann","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1016\/S0140-6736(11)61940-5","article-title":"Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin\u2019s lymphoma (HD15 trial): A randomised, open-label, phase 3 non-inferiority trial","volume":"379","author":"Engert","year":"2012","journal-title":"Lancet"},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Gallamini, A., Kurlapski, M., and Zaucha, J.M. (2021). FDG-PET\/CT for the Management of Post-Chemotherapy Residual Mass in Hodgkin lymphoma. Cancers, 13.","DOI":"10.3390\/cancers13163952"},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Vassilakopoulos, T.P., Liaskas, A., Pereyra, P., Panayiotidis, P., Angelopoulou, M.K., and Gallamini, A. (2023). Incorporating Monoclonal Antibodies into the First-Line Treatment of Classical Hodgkin Lymphoma. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241713187"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1200\/JCO.21.01281","article-title":"Brentuximab Vedotin Plus AVD for First-Line Treatment of Early-Stage Unfavorable Hodgkin Lymphoma (BREACH): A Multicenter, Open-Label, Randomized, Phase II Trial","volume":"41","author":"Fornecker","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1200\/JCO.22.02355","article-title":"Nivolumab and Doxorubicin, Vinblastine, and Dacarbazine in Early-Stage Unfavorable Hodgkin Lymphoma: Final Analysis of the Randomized German Hodgkin Study Group Phase II NIVAHL Trial","volume":"41","author":"Meissner","year":"2023","journal-title":"J. Clin. Oncol."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/60\/2\/344\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:02:11Z","timestamp":1760104931000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/60\/2\/344"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,19]]},"references-count":92,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,2]]}},"alternative-id":["medicina60020344"],"URL":"https:\/\/doi.org\/10.3390\/medicina60020344","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,19]]}}}